Chief Legal Officer · Immunome Inc. (IMNM)

Sandra Stoneman

A named executive officer of Immunome in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,246,699

Salary $470,000Stock awards $0

FY2020: $1,314,397

3rd of 3 named executive officers at Immunome by FY2024 total.

3 named officers on file for Immunome, FY2024

Sandra Stoneman’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunome’s whole pay program stands against its peers

  • Immunome’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Sandra Stoneman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Sandra Stoneman compensation by year

Immunome Summary Compensation Table · all 2 fiscal years held
In US dollars, as Immunome reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2024
Salary$71,571$470,000
Bonus$15,000—
Stock awards$0$0
Option awards$1,196,828$4,531,349
Non-equity incentive$30,632$235,000
Pension and deferred compensation$0$0
All other$366$10,350
Total$1,314,397$5,246,699

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunome Inc. DEF 14A filed April 24, 2025, accession 0001140361-25-015421, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunome Inc. filed document, accession 0001140361-25-015421. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

$1.3M
$5.2M
FY20
FY24
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option12,375—$3.42
Option35,000—$4.84
Option1,731—$20.92
Option210,000—$12.92
Option200,000—$16.57

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunome Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2024 proxy (filed April 24, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-23Grant or award—38,250$0.0043,805
2026-07-23Grant or award derivative—76,500$0.0076,500
2025-07-29Grant or award derivative—190,000$0.00190,000

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Immunome’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Clay SiegallPresident, Chief Executive Officer and Chairman of the Board$9,226,774
Kinney HornChief Business Officer$6,989,668
Sandra Stoneman · this pageChief Legal Officer$5,246,699

Board service

Immunome board · FY2024

How this board is paid

Company policy: Immunome pays directors a $40,000 cash retainer and $135,000 in Options. As stated in Immunome's FY2024 proxy.

The full Immunome compensation record

free company brief

This page is one person within Immunome's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunome's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sandra Stoneman's compensation dossier · One-time report. No refunds.